Emerging Growth Drivers in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Landscape: Surging Prevalence Of Ovarian Cancer Fuels Growth In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market
Discover trends, market shifts, and competitive outlooks for the poly adp-ribose polymerase (parp) inhibitor industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
#How Has the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Growth Performance Trended Historically, And What Lies Ahead?3
The market size of the Poly ADP-ribose polymerase (PARP) inhibitor has witnessed a swift expansion in the last few years. Its progression from $8.39 billion in 2024 to an anticipated $9.41 billion in 2025, with a compound annual growth rate (CAGR) of 12.1% illustrates this trend. Clinical research, regulatory green lights, market rivalry, drug amalgams, and patient support can all account for the growth observed during this historical period.
Expectations indicate a brisk expansion in the market size of the poly ADP-ribose polymerase (PARP) inhibitor in the forthcoming years. The market is set to surge to a value of $14.67 billion by 2029, with a compound annual growth rate (CAGR) of 11.7%. Factors contributing to this predicted growth include the enlargement of indications, bespoke medicine, the establishment of biomarkers, healthcare economics, and budding markets. The period of prediction also displays significant trends such as precision medicine, advancements in immunotherapy, targeted treatment options, the application of artificial intelligence in drug discovery, and a patient-focused approach to healthcare.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp
Which Factors and External Forces Are Driving Demand in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
The rising occurrence of ovarian cancer is anticipated to fuel the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market in the future. Ovarian cancer, a malignant tumor that forms in one or both of a woman’s ovaries, is part of the female reproductive system that is responsible for the production of eggs and female hormones. Factors such as genetic predisposition, an aging demographic, environmental exposures, and hormonal imbalances contribute to the growth of ovarian cancer. Poly ADP-Ribose Polymerase (PARP) Inhibitors, which target DNA repair mechanisms, particularly in patients with BRCA mutations that result in synthetic lethality and enhanced tumor cell death, are employed in ovarian cancer treatment. For example, the World Ovarian Cancer Coalition, a non-profit organization based in Canada, projected in February 2024 that the annual number of women dying from ovarian cancer will increase to 350,956, a surge of nearly 70% from 2022. Thus, the escalating occurrence of ovarian cancer is driving the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market.
Which Primary Segments of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Are Driving Growth and Industry Transformations?
The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented –
1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers
4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15637&type=smp
What Are the Fastest-Growing Geographies in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Industry?
Leading businesses in the poly ADP-ribose polymerase (PARP) inhibitor market are creating generic PARP inhibitors to provide a customized treatment method for cancer patients with particular genetic mutations. These medications impede the function of the enzyme poly ADP-ribose polymerase (PARP). For example, in March 2024, Zydus Lifesciences Limited, a pharmaceutical firm headquartered in India, launched Olaparib, a PARP inhibitor under the IBYRA brand, with the goal of improving access to sophisticated cancer therapy. IBYRA is designed to target distinct genetic mutations found in breast, ovarian, prostate, and pancreatic cancers, thereby giving a precise and effective treatment strategy. This drug is especially advantageous for patients with HRD-positive or BRACA mutations, as it aids in slowing the progression of the disease.
View the full report here:
What Parameters Are Used to Define the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
Poly ADP-ribose polymerase (PARP) inhibitors are a class of pharmacological inhibitors that block the enzyme PARP, which is involved in deoxyribonucleic acid (DNA) repair. These inhibitors treat cancers with defects in other DNA repair pathways, preventing cancer cells from repairing damaged DNA and leading to their death.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15637
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
